US 12,329,762 B2
Pharmaceutical preparation for improving absorption and postprandial hypoglycemic action of insulin
Jean-Luc Ardilouze, Sherbrooke (CA); Maude Gagnon-Auger, Sherbrooke (CA); Fernand Gobeil, Sherbrooke (CA); Julie Menard, Sherbrooke (CA); Jean-Patrice Baillargeon, Sherbrooke (CA); and Pascal Brassard, Magog (CA)
Assigned to ELI LILLY AND COMPANY, Indianapolis, IN (US)
Filed by Eli Lilly and Company, Indianapolis, IN (US)
Filed on Jan. 19, 2023, as Appl. No. 18/156,633.
Application 18/156,633 is a continuation of application No. 15/747,532, abandoned, previously published as PCT/CA2016/050886, filed on Jul. 28, 2016.
Claims priority of provisional application 62/197,833, filed on Jul. 28, 2015.
Prior Publication US 2023/0158043 A1, May 25, 2023
Int. Cl. A61K 31/5578 (2006.01); A61K 9/00 (2006.01); A61K 31/137 (2006.01); A61K 31/472 (2006.01); A61K 31/519 (2006.01); A61K 31/557 (2006.01); A61K 31/5585 (2006.01); A61K 38/28 (2006.01); A61K 45/06 (2006.01); A61P 3/10 (2006.01); C07D 215/20 (2006.01); C07D 217/20 (2006.01); C07D 487/04 (2006.01); C07K 14/62 (2006.01)
CPC A61K 31/5578 (2013.01) [A61K 9/0019 (2013.01); A61K 31/137 (2013.01); A61K 31/472 (2013.01); A61K 31/519 (2013.01); A61K 31/557 (2013.01); A61K 31/5585 (2013.01); A61K 38/28 (2013.01); A61K 45/06 (2013.01); A61P 3/10 (2018.01); C07D 215/20 (2013.01); C07D 217/20 (2013.01); C07D 487/04 (2013.01); C07K 14/62 (2013.01)] 8 Claims
 
1. A method for treating diabetes comprising simultaneously administering subcutaneously to the same site in a subject in need thereof, a therapeutically effective amount of a short-acting insulin analog (SAIA) and a subcutaneously vasoactive effective amount of iloprost; wherein the ratio of SAIA to iloprost is 10-30 U SAIA: about 1 nmol iloprost; wherein the vasoactive effective amount of iloprost causes a local increase of blood flow in subcutaneous adipose tissue.